High yield engineered nanovesicles from ADSC with enriched miR-21-5p promote angiogenesis in adipose tissue regeneration
Source abstract
Abstract
Abstract Background Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have been found to have a great potential for soft tissue repair due to various biological functions, including pro-angiogenesis and low immunogenicity. However, the low yield and heterogeneity of MSC-EVs limited their clinical transformation. This study was designed to develop a novel adipose-derived stem cell engineered nanovesicles (ADSC-NVs) with high production and explore its pro-angiogenetic effect and application in adipose tissue regeneration. Methods Adipose-derived stem cell-derived extracellular vesicles (ADSC-EVs) were isolated from an EVs-free culture medium for human ADSCs (hADSCs). ADSC-NVs were prepared by sequentially extruding ADSCs followed by iodixanol density gradient ultracentrifugation and were compared with ADSC-EVs in morphology, size distribution, protein contents and yield. The pro-angiogenetic effect of ADSC-NVs in different doses (0, 5, 20 and 80 μg/mL) in vitro was determined using transwell assay, tube formation assay, western blot and qRT-PCR. In vivo, BALB/c nude mice were administered injection of a mixture of fat granules and different dose of ADSC-NVs and grafts were harvested at 12 weeks post-transplantation for further analysis. By analyzing the weight and volume of grafts and histological evaluation, we investigated the effect of ADSC-NVs in vessel formation and adipose tissue regeneration. Results Our results showed yield of purified ADSC-NVs was approximately 20 times more than that of ADSC-EVs secreted by the same number of ADSCs. In vitro, both ADSC-NVs and ADSC-EVs exhibited a dose-dependent pro-angiogenetic effect, despite their distinct miRNA profiles. These effects of ADSC-NVs may be mediated by enriched miR-21-5p via PTEN inhibition and PI3K/p-Akt signaling activation. Furthermore, after a mixed injection of ADSC-NVs, vessel formation and adipose regeneration were observed in vivo in fat implants. Conclusions Our study developed a potent alternative of ADSC-EVs. ADSC-NVs have a high pro-angiogenesis potential and can be used as cell-free therapeutic biomaterials in soft tissue regeneration.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Extracellular vesicles in disease · Mesenchymal stem cell research · Tissue Engineering and Regenerative Medicine
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Plastic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Wuhan Clinical Research Center for Superficial Organ Reconstruction, Wuhan 430022, China.
Funding
National Key R&D Program of China · National Natural Science Foundation of China · Fundamental Research Funds for the Central Universities
References (59)
Show source-provided references
1. 10.1038/s41551-020-00674-w10.1038/s41551-020-00674-w ↗
2. 10.1097/PRS.000000000000604610.1097/PRS.0000000000006046 ↗
3. 10.1021/acsami.0c2267110.1021/acsami.0c22671 ↗
4. 10.1021/acsami.9b1701510.1021/acsami.9b17015 ↗
5. 10.1021/acsami.0c0660910.1021/acsami.0c06609 ↗
6. 10.1186/s40824-016-0068-010.1186/s40824-016-0068-0 ↗
7. 10.1021/acs.nanolett.0c0092910.1021/acs.nanolett.0c00929 ↗
8. 10.1021/acsami.9b1012610.1021/acsami.9b10126 ↗
9. 10.1186/s40824-021-00220-y10.1186/s40824-021-00220-y ↗
10. 10.1186/s40824-021-00224-810.1186/s40824-021-00224-8 ↗
11. 10.1016/j.tibtech.2021.04.00610.1016/j.tibtech.2021.04.006 ↗
12. 10.1016/j.biomaterials.2012.09.02110.1016/j.biomaterials.2012.09.021 ↗
13. 10.1016/j.biomaterials.2021.12084110.1016/j.biomaterials.2021.120841 ↗
14. 10.1016/j.cmet.2019.07.01110.1016/j.cmet.2019.07.011 ↗
15. 10.7150/thno.1891510.7150/thno.18915 ↗
16. 10.1016/j.ymthe.2018.09.01510.1016/j.ymthe.2018.09.015 ↗
17. 10.1002/jev2.1226610.1002/jev2.12266 ↗
18. 10.1186/1471-2407-12-42110.1186/1471-2407-12-421 ↗
19. 10.1021/acsnano.0c0512210.1021/acsnano.0c05122 ↗
20. 10.1016/j.jconrel.2021.10.01910.1016/j.jconrel.2021.10.019 ↗
21. 10.1038/nrm.2017.12510.1038/nrm.2017.125 ↗
22. 10.1002/adhm.20210049210.1002/adhm.202100492 ↗
23. 10.1126/sciadv.aba688410.1126/sciadv.aba6884 ↗
24. 10.7150/thno.3446410.7150/thno.34464 ↗
25. 10.1021/acsnano.9b0438410.1021/acsnano.9b04384 ↗
26. 10.1073/pnas.141004111110.1073/pnas.1410041111 ↗
27. 10.1016/j.addr.2018.12.00910.1016/j.addr.2018.12.009 ↗
28. 10.1016/j.biomaterials.2014.07.04710.1016/j.biomaterials.2014.07.047 ↗
29. 10.1039/C4NR02391A10.1039/C4NR02391A ↗
30. Kim J Han C Jo W Kang S Cho S Jeong D et al. Cell-engineered Nanovesicle as a surrogate inducer of contact-dependent stimuli. Adv Healthc Mater. 2017;6(17):1700381.10.1002/adhm.201700381 ↗
31. 10.1021/acsnano.5b0299710.1021/acsnano.5b02997 ↗
32. 10.1126/sciadv.aaz095210.1126/sciadv.aaz0952 ↗
33. 10.1039/C3LC50993A10.1039/C3LC50993A ↗
34. 10.1016/j.biomaterials.2015.04.02810.1016/j.biomaterials.2015.04.028 ↗
35. 10.1038/s41392-021-00765-310.1038/s41392-021-00765-3 ↗
36. 10.1088/1758-5090/ab52ea10.1088/1758-5090/ab52ea ↗
37. 10.1097/PRS.0b013e3181811ff010.1097/PRS.0b013e3181811ff0 ↗
38. 10.1080/20013078.2018.153575010.1080/20013078.2018.1535750 ↗
39. 10.1038/s41467-021-25839-210.1038/s41467-021-25839-2 ↗
40. 10.1021/acsami.1c0804410.1021/acsami.1c08044 ↗
41. 10.1186/s40824-021-00218-610.1186/s40824-021-00218-6 ↗
42. 10.1038/s41580-020-0251-y10.1038/s41580-020-0251-y ↗
43. 10.1016/j.celrep.2019.08.03610.1016/j.celrep.2019.08.036 ↗
44. 10.1182/blood-2017-07-74639610.1182/blood-2017-07-746396 ↗
45. 10.7150/thno.3735710.7150/thno.37357 ↗
46. 10.1016/j.stem.2012.02.00810.1016/j.stem.2012.02.008 ↗
47. 10.1634/stemcells.2008-026110.1634/stemcells.2008-0261 ↗
48. 10.1016/j.cub.2005.06.06210.1016/j.cub.2005.06.062 ↗
49. 10.1038/nrneph.2017.14810.1038/nrneph.2017.148 ↗
50. 10.1007/s11010-014-2303-010.1007/s11010-014-2303-0 ↗
51. 10.1155/2013/19242510.1155/2013/192425 ↗
52. 10.1126/science.aau697710.1126/science.aau6977 ↗
53. 10.1016/j.ymthe.2021.03.01510.1016/j.ymthe.2021.03.015 ↗
54. 10.1016/j.ccr.2005.12.02110.1016/j.ccr.2005.12.021 ↗
55. 10.1016/j.mtbio.2021.10017110.1016/j.mtbio.2021.100171 ↗
56. 10.1016/S0092-8674(02)00969-810.1016/S0092-8674(02)00969-8 ↗
57. 10.1161/ATVBAHA.115.30708510.1161/ATVBAHA.115.307085 ↗
58. 10.1126/scitranslmed.aaz869710.1126/scitranslmed.aaz8697 ↗
59. 10.1038/nm0405-36710.1038/nm0405-367 ↗